Indonesia’s Court Ruling on Patent Evergreening Exposes Global Pharma’s Access Barriers, Forcing Reckoning with Intellectual Property as a Public Health Tool
Original framing: “STAT+: Indonesian ruling against ‘patent evergreening’ by pharma industry sends critical message, patient advocates say” — STAT News
The practice of patent evergreening is not a new phenomenon but a direct descendant of colonial-era pharmaceutical exploitation, where European and American companies patented medicinal plants and compounds extracted from Indigenous and global South communities without compensation. The 1886 Bayh-Dole Act in the U.S., which incentivized university and corporate patenting, was later weaponized by pharmaceutical giants to extend monopolies on drugs like HIV treatments in the 1990s. Indonesia’s 2010 Bayer case was a direct response to this history, and the 2023 ruling builds on it by reinforcing that national sovereignty over patent laws is a legitimate tool for correcting past injustices. The TRIPS agreement (1994), which many low-income countries resisted, further institutionalized these corporate privileges, making Indonesia’s defiance a rare but significant challenge to the global IP order.
The Indonesian court’s ruling against patent evergreening is not merely a legal victory but a systemic disruption of a global pharmaceutical power structure that has historically prioritized corporate profit over public health access.
This decision builds on a long history of resistance—from Indonesia’s 2010 Bayer lawsuit to Brazil’s 1990s compulsory licensing of HIV drugs—demonstrating that when political will aligns with public health imperatives, even entrenched patent monopolies can be challenged. The ruling also restores a cross-cultural perspective on medicine as a communal good, aligning with Indigenous and global South traditions that view healing knowledge as a shared heritage rather than a proprietary asset. By centering marginalised voices—such as those of Indonesian patients and generic drug manufacturers—this decision exposes the human cost of evergreening and forces a reckoning with the role of intellectual property in shaping health equity. The trickster logic of the court’s approach, using the system’s own rules to dismantle it, models a pathway for future resistance, while future modelling suggests that collective action could trigger a domino effect, reducing global drug prices and expanding access for millions. Ultimately, this ruling is a call to reimagine medicine as a public good, not a corporate commodity, and to reclaim agency over health systems from the grip of pharmaceutical corporations.